Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
JAJazz Pharmaceuticals plc logo

Jazz Pharmaceuticals plc (JAZZ)

NASDAQ · Currency in USD
$214.00 ▼ -0.65 (-0.30%)
At close: Oct 23, 4:00 PM ET. Market closed.
$214.20 ▲ +0.20 (+0.09%)
After hours: Oct 23, 7:44 PM ET

Summary

Previous Close
$214.65
Open
$213.83
Day's Range
$211.49 – $215.35
52 Week Range
$128.80 – $266.38
Volume
560,589
Avg. Volume
860,583
Market Cap
$13.89B
Beta (5Y Monthly)
0.32
PE Ratio (TTM)
14.08
EPS (TTM)
$14.89
Earnings Date
Nov 2, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$292.27

Profile: Jazz Pharmaceuticals plc

Sector
Healthcare
Industry
Biotechnology
Full-time employees
2,890
CEO
Renee D. Gala

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia.

Earnings

Next report: Mon, Nov 2, 2026
EPS estimate $6.26 · Revenue est. $1.21B
DateEst.Actual
Aug 3, 2026$6.18$5.71Miss
May 5, 2026$4.64$6.34Beat
Feb 24, 2026$6.52$6.64Beat
Nov 5, 2025$5.95$8.13Beat
Aug 5, 2025-$6.12-$8.25Miss
May 6, 2025$4.51$1.68Miss

Analyst view

Consensus price target
$292.27 ▲ +36.6%
Range $229.00 – $337.00
Rating: Buy
Buy 90% · Hold 10% · Sell -0%

Get free alerts on JAZZ and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.